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Comparison of bi- and multiparametric
magnetic resonance imaging to select
men for active surveillance
Karen-Cecilie D. Thestrup1 , Vibeke Løgager1 ,
Lars Boesen2 and Henrik S. Thomsen1
Abstract
Background: Active surveillance of men with prostate cancer relies on accurate risk assessments because it aims to
avoid or delay invasive therapies and reduce overtreatment.
Purpose: To compare the diagnostic performance of pre-biopsy biparametric magnetic resonance imaging (MRI) with
confirmatory multiparametric MRI in selecting men for active surveillance.
Material and Methods: The study population included biopsy-naı¨ve men with clinical suspicion of prostate cancer
undergoing biparametric MRI followed by combined (standard plus MRI targeted) biopsies. Men diagnosed with prostate
cancer who were subsequently enrolled in active surveillance and underwent a confirmatory multiparametric MRI within
three months of diagnosis were included in the study. Discrepancies between the pre-biopsy biparametric MRI and the
confirmatory multiparametric MRI were assessed.
Results: Overall, 101 men (median age¼ 64 years; median prostate-specific-antigen level¼ 6.3 ng/mL) were included.
Nine patients were re-biopsied after multiparametric MRI for the following reasons: suspicion of targeting error (three
patients); a new suspicious lesion detected by multiparametric MRI (five patients); and an increase in tumor volume (one
patient) compared with biparametric MRI. Confirmatory biopsies showed a Gleason grade group (GG) upgrade of 2 in
4/6 patients with suspicion of more advanced disease (missed suspicious lesion, increase in tumor volume) on multi-
parametric MRI. However, although multiparametric MRI subsequently detected a GG  2 prostate cancer lesion missed
by biparametric MRI in 4% (4/101) of included men, the difference did not reach statistical significance
(McNemar, P¼ 0.133).
Conclusion: Biparametric MRI could be used to select men eligible for active surveillance and a confirmatory multi-
parametric MRI performed shortly after inclusion seems unnecessary.
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Introduction
Treatment for prostate cancer (PCa) ranges from inva-
sive radical interventions, such as radical prostatecto-
my and radiotherapy, to non-invasive observational
strategies that include either watchful waiting or
active surveillance (AS) (1). AS is a well-established
surveillance program for men with low-risk PCa that
aims to reduce overtreatment and avoid or delay inva-
sive interventions with their inherent side effects, e.g.
impotence and incontinence (2). Men enrolled in AS
are monitored closely using prostate-specific-antigen
(PSA) measurements, digital-rectal examinations, and
biopsies. Active treatment can be initiated in response
to disease progression (2). However, AS is heavily
dependent on accurate risk assessments including
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tumor localization, volume, and Gleason score (GS)
grading. Diagnosis of PCa currently relies on transrec-
tal ultrasonography-guided biopsies (TRUS-bx).
However, TRUS-bx are prone to sampling errors
and clinically significant PCas may be missed by
the random untargeted sampling method (3).
Multiparametric (mp) magnetic resonance imaging
(MRI) has emerged as a non-invasive diagnostic tool
for improved PCa risk assessment with a high negative
predictive value (NPV) for ruling out significant dis-
ease. Thus, a confirmatory mpMRI may be used in
men enrolled in AS for lesion characterization and
staging to identify potentially missed clinically signifi-
cant PCas for confirmatory targeted biopsies or to
rule out aggressive disease and confirm eligibility for
AS (4–7). At present, the European Association of
Urology guideline recommends using mpMRI when a
patient is enrolled in AS to confirm their eligibility (1).
However, it is not specified at what time point during
follow-up it should be performed. Furthermore, it was
recently demonstrated that biparametric (bp)MRI
improves PCa risk stratification, has a high NPV for
ruling out significant disease in biopsy-naı¨ve men, and
may be used to avoid unnecessary biopsies (8–11).
Compared with mpMRI, bpMRI is simpler and
quicker with fewer scan sequences and no contrast
agent. In addition, mpMRI is associated with greater
costs and prolonged magnet-time. However, although
bpMRI seems to improve PCa risk stratification of
biopsy-naı¨ve men in an initial detection setting (suspi-
cion of PCa), it is unclear whether it can be further used
for lesion characterization and staging to select men
eligible for AS, which constitutes a different patient
cohort with known low-risk PCa. Therefore, we com-
pared the diagnostic performance of pre-biopsy
bpMRI and confirmatory mpMRI scans in selecting
men eligible for AS and assessed whether bpMRI
missed suspicious PCa lesions that were subsequently
detected by mpMRI.
Material and Methods
Our study population was derived from a prospective
database (12) used to assess the diagnostic accuracy of
bpMRI for PCa detection in biopsy-naı¨ve men. This
database included 1020 biopsy-naı¨ve men with clinical
suspicion of PCa who underwent bpMRI followed by
combined biopsies (TRUS-bx and targeted biopsies of
any Prostate Imaging Reporting and Data System
[PI-RADS] 3 lesion). Overall, PCa was detected in
655 of the 1020 men; 180 of these 655 men were sub-
sequently enrolled in AS based on national guidelines
(12) or patient preference. The primary inclusion crite-
rion for AS was men with low-risk PCa (i.e. tumor
stage T2a, PSA 10 ng/mL, and GS 6). However,
well-informed men with limited intermediate-risk
PCa (cT2b, PSA¼ 10–20 ng/mL, or GS¼ 3þ 4 in
only 1–2 biopsy cores) could be enrolled based on
patient preference. All patients underwent a confirma-
tory mpMRI as part of the departments’ diagnostic
workup within the first year of entering AS. Of these,
101/180 men fulfilled the inclusion criteria and under-
went an mpMRI within the first three months. These
men constituted the final patient cohort for this study.
BpMRI and MpMRI
All MRIs (bpMRI and mpMRI) were performed using
a 3-T MRI magnet (Ingenia version 5.3.1, Philips
Healthcare, Best, the Netherlands) with a 16-channel
surface coil and a built-in table coil (Philips
Healthcare) positioned over the pelvis. No post-
acquisition filtering was applied outside what is
denoted “default” by the scanner vendor (Philips).
BpMRI was performed before biopsies of the prostate.
The bpMRI protocol included axial T2-weighted
(T2W) and diffusion-weighted (DWI) imaging with
reconstructions of the corresponding apparent diffu-
sion coefficient maps and image acquisition times of
approximately 15min. In contrast to the bpMRI pro-
tocol, the mpMRI protocol included triplanar T2W
imaging and dynamic contrast-enhanced T1-weighted
(T1W) imaging sequences in the axial plane.
Furthermore, anti-peristaltic drugs (hyoscinbutylbro-
mid [20mg/mL Buscopan injection fluid; Boehringer
Ingelheim GmbH, Ingelheim am Rhein, Germany]
and glucagon [1mg GlucaGen; Novo Nordisk A/S,
Bagsværd, Denmark]) were administered if tolerated.
The mpMRI procedure consisted of preparing and
positioning the patient, establishing intravenous
access (approximately 15min), and image acquisition
(approximately 30min). This enables us to perform
two bpMRI scans per hour or one mpMRI scan per
hour. The mpMRI and bpMRI protocol details are
listed in Table 1. All MRI scans were reviewed by the
same prostate MRI physician (>6 years of experience),
who registered and scored any suspicious lesions on a
5-point scale according to their likelihood of being sig-
nificant PCas (1¼ highly unlikely; 2¼ unlikely;
3¼ equivocal; 4¼ likely; and 5¼ highly likely) using
the PI-RADS version 2 criteria (13). The reader was
aware of the bpMRI when reporting the mpMRI.
Patients with no suspicious lesions were assigned a
PI-RADS score of 1. However, as the bpMRI protocol
did not include dynamic contrast-enhanced imaging,
scoring of lesions in the peripheral zone relied solely
on DWI findings (i.e. the dominant sequence).
Therefore, an equivocal score of 3 was not upgraded
to a score of 4 due to a lack of positive dynamic
contrast-enhanced findings. An MRI suspicion
2 Acta Radiologica Open
T
a
b
le
1
.
M
p
M
R
I
an
d
b
p
M
R
I
p
ro
to
co
ls
.
m
p
M
R
I
T
R
(m
s)
T
E
(m
s)
FO
V
(m
m
)
M
at
ri
x
b
va
lu
e
s
N
A
S
Sl
ic
e
(m
m
)
Sc
an
ti
m
e
(m
in
:s
)
Te
m
p
re
s
(s
)
T
2
sa
gi
tt
al
3
0
0
0
9
0
1
6
0

1
9
8
2
6
8

3
2
6
–
2
3
0
6
:0
6
–
T
2
ax
ia
l
4
0
0
0
9
0
1
8
0

1
8
0
4
0
0

4
0
0
–
1
3
0
9
:1
9
–
D
W
I
ax
ia
l
1
3
,7
4
3
7
1
1
8
0

1
8
0
8
4

8
0
0
;
1
0
0
;
8
0
0
;
2
0
0
0
2
4
0
6
:3
3
–
T
2
co
ro
n
al
3
5
0
4
9
0
1
9
0

1
9
0
3
1
6

3
1
2
–
1
3
0
4
:1
6
–
D
C
E
1
0
5
1
8
0

1
5
8
2
5
6

2
2
1
–
1
5
0
3
.0
3
0
0
.1
5
A
C
Q
vo
x
e
l
R
E
C
vo
x
e
l
SE
N
SE
fa
ct
o
r
H
al
f
sc
an
fa
ct
o
r
B
W
T
2
sa
gi
tt
al
0
.6

0
.6

3
0
.3

0
.3

3
N
/A
N
/A
5
3
0
T
2
ax
ia
l
0
.4
5

0
.4
5

3
0
.2
2

0
.2
2

3
N
/A
N
/A
2
1
9
D
W
I
ax
ia
l
2
.2

2
.2

3
0
.8

0
.8

3
2
0
.6
9
8
1
5
(2
7
7
9
in
E
P
I
fr
e
q
.
d
ir
.)
T
2
co
ro
n
al
0
.6

0
.6

3
0
.2
2

0
.2
2

3
1
.2
N
/A
2
1
7
D
C
E
0
.7

0
.7

1
0
.4
0
.7

0
.7

5
.2
2
.2
(A
P
)
1
(F
H
)
0
.6
2
5
(y
)
1
(z
)
1
3
5
b
p
M
R
I
T
R
(m
s)
T
E
(m
s)
FO
V
(m
m
)
M
at
ri
x
b
va
lu
e
s
N
A
S
Sl
ic
e
(m
m
)
Sc
an
ti
m
e
(m
in
:s
)
Te
m
p
re
s
(s
)
T
2
sa
gi
tt
al
(s
co
u
t)
3
.3
1
.6
5
2
7
0

2
7
0
1
8
0

1
8
0
–
2
3
0
0
:2
9
–
T
2
ax
ia
l
3
4
7
5
9
0
1
8
0

1
8
0
4
0
0

4
0
0
–
1
3
0
8
:1
4
–
D
W
I
ax
ia
l
1
0
,0
0
0
7
1
1
8
0

1
8
0
8
4

8
0
0
;
1
0
0
;
8
0
0
;
2
0
0
0
2
4
0
6
:3
0
–
A
C
Q
vo
x
e
l
R
E
C
vo
x
e
l
SE
N
SE
fa
ct
o
r
H
al
f
sc
an
fa
ct
o
r
B
W
T
2
sa
gi
tt
al
(s
co
u
t)
1
.5

1
.5

3
0
.8
4

0
.8
4

3
N
/A
N
/A
1
4
1
7
T
2
ax
ia
l
0
.4
5

0
.4
5

3
0
.2
2

0
.2
2

3
N
/A
N
/A
2
1
9
D
W
I
ax
ia
l
2
.2

2
.2

4
0
.8

0
.8

4
2
0
.6
9
8
1
5
(2
7
7
9
in
E
P
I
fr
e
q
.
d
ir
.)
m
p
M
R
I,
m
u
lt
ip
ar
am
et
ri
c
m
ag
n
e
ti
c
re
so
n
an
ce
im
ag
in
g;
b
p,
b
ip
ar
am
e
tr
ic
(M
R
I)
;
T
R
,
re
p
e
ti
ti
o
n
ti
m
e
;
T
E
,
e
ch
o
ti
m
e
;
FO
V
,
fie
ld
o
f
vi
ew
;
N
SA
,
n
u
m
b
er
o
f
si
gn
al
av
e
ra
ge
s;
Te
m
p
re
s,
te
m
p
o
ra
l
re
so
lu
ti
o
n
;
D
W
I,
d
iff
u
si
o
n
-w
e
ig
h
te
d
im
ag
e
s;
D
C
E
,
d
yn
am
ic
co
n
tr
as
t-
e
n
h
an
ce
d
;
B
W
,
b
an
d
w
id
th
.
Thestrup et al. 3
score  2 was considered a low-suspicion or negative
MRI result. MpMRI results were compared to the ini-
tial bpMRI examination and deemed equivalent if no
new lesions were detected or if a lesion did not increase
in PI-RADS score or volume. Because the bpMRIs
only included one-dimensional axial T2W images,
three-dimensional tumor volumes could only be
assessed on mpMRI. As a result, an increase in
tumor volume comparing bpMRI and mpMRI results
was assessed subjectively by the reader for example by
comparing slices for comparing, if relevant. All patients
were discussed at a multidisciplinary conference that
included urologists and radiologists, on which biopsy
and MRI results were analyzed in consensus. If there
was a mismatch between the PI-RADS assessment cat-
egory/MRI suspicion (e.g. large tumor, low ADC
value, invasive behavior) and the biopsy results (e.g.
benign targeted biopsy or limited GS 6 tumor), then
biopsy targeting error was suspected and a re-biopsy
was recommended. Similarly, any patient with a new
suspicious lesion or an increase in tumor volume on
mpMRI was referred for re-biopsy if the result of
such could potentially change the patients clinical man-
agement. As our fusion-biopsy system does not allow
for recording of the needle-tracts, prior biopsy sites
could not be retrospectively checked.
Histopathological evaluation
The same genitourinary pathologist (>15 years of expe-
rience) reviewed all biopsy samples. When reviewing
the biopsy cores, the pathologist was aware whether
it was a systematic biopsy or a targeted biopsy. For
each PCa-positive biopsy core, the location, the GS
based on the International Society of Urological
Pathology 2005 consensus (14), and the percentage of
cancerous tissue per core were determined. In addition,
patients were assigned International Society of
Urological Pathology 2014 consensus Gleason grade
groups (GGs) (15). Repeat biopsy results were com-
pared to the original diagnostic biopsies.
Statistical analysis
Descriptive statistics were used to present patient char-
acteristics. Continuous variables (i.e. age, PSA level,
PSA density, and prostate volume) are described
using medians, standard deviations, and ranges.
Normality was tested using Kolmogorov–Smirnov
test and a P value< 0.05 was considered statistically
significant. Differences between the initial bpMRI
scans and the mpMRI scans were evaluated using
McNemar’s and chi-square tests. PI-RADS risk assess-
ment groups from bpMRI and mpMRI were stratified
into negative (PIRADS 1 and 2), equivocal (PIRADS
3), and positive (PIRADS 4 and 5) findings; intra-
reader agreement was calculated using Cohen’s
Kappa. Statistical analysis was performed using
Rstudio software (ver. 1.1.5; RStudio, Inc., Boston,
MA, USA) and a two-sided P value< 0.05 was consid-
ered statistically significant (16).
Results
In total, 101 men (median age¼ 64 years; median
PSA¼ 6.3 ng/mL) met the requirements for inclusion
in the study. The variables are normality distributed.
Time from the initial bpMRI to the confirmatory
mpMRI was median 84 days 15 SD (range¼ 59–114
days). There was no significant difference comparing
the distribution of PI-RADS risk assessment categories
from bpMRI with mpMRI (Fig. 1). The majority of
patients (85%) had clinically non-palpable tumors at
stage cTx–T1c, while 11% had cT2a and 4% had
cT2b tumors. Patient characteristics are listed in
Table 2. Overall, the MRI reader assessment changed
in 11 cases after confirmatory mpMRI for the follow-
ing reasons: upgrade in PI-RADS assessment category
from PI-RADS 3 to 4 (two cases); increase in tumor
volume (three cases); and detection of new lesions (six
cases). One of the upgrades from PI-RADS 3 to 4 was
caused by positive DCE, but it did not have any clinical
consequence, as both PI-RADS 3 and 4 lesions were
biopsied in the initial setting. The other one was re-
biopsied. Although, three increased in volume, two of
them were not re-biopsied because it was decided at the
multidisciplinary consensus conference that it did not
have any clinical consequence for the patients. The six
new lesions were: one PI-RADS 3 which was consid-
ered to be sampled by the standard biopsies and there-
fore not re-biopsied; one PI-RADS 3, which appeared
secondary to a PI-RADS 5 lesion and therefore not re-
biopsied; and finally four which were re-biopsied (two
PI-RADS 3 and two PI-RADS 4; Table 3). Post-biopsy
hemorrhage was present in 62% (n¼ 63) of mpMRI
scans. Where 53% (n¼ 54) influenced the images.
BpMRI had 8% (n¼ 8) susceptibility artifacts with
partial effect on the images, 1% (n¼ 1) with no effect
on the images, and 1% (n¼ 1) with effect on the
images. Concerning rectal gas, bowl movement, or
patient movement: MpMRI had 7% (n¼ 7) suscepti-
bility artifacts with partial effect on the outcome of the
scan, 2% (n¼ 2) with no effect on the outcome of the
scan, and 1% (n¼ 1) with effect on the outcome of the
scan. The intra-reader agreement comparing bpMRI to
mpMRI was high (Cohen’s Kappa¼ 0.94; Table 4).
Overall, nine patients underwent a confirmatory re-
biopsy after mpMRI (Table 3 and Figs. 2–7). Five of
them were caused by a change in the reader assessment.
The decision to refer patients for re-biopsy was
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initiated at the discretion of the treading urologist and
radiologist in consensus at the multidisciplinary team
conference and based upon: (i) suspicion of targeting
error of initial biopsies (n¼ 3); (ii) a new lesion detected
(n¼ 4); or (iii) a significant increase in tumor volume
(n¼ 1) comparing mpMRI to bpMRI. However, one
was re-biopsied because the histopathologist was not
satisfied with the material required at the biopsy
(patient 6, n¼ 1). As a result, the remaining (n¼ 92)
patients did not undergo immediate re-biopsy, either
because the mpMRIs and bpMRIs were diagnostic
comparable or because a re-rebiopsy would not
change the clinical management of the patient. For
example, patient 4 had suspicion of targeting error of
the initial biopsies, because he had a large anterior PI-
RADS 5 lesion (ADC 0.51) on bpMRI, but only GG 1
PCa on targeted biopsy (Figs. 4 and 5). This might be
explained by PCa heterogeneity where larger lesions
often harbor areas of mixed cancer aggressiveness
within the same lesion. The discrepancy between the
biopsy result and the MRI lead to re-biopsy that revealed
a GG 3 tumor. Of the six patients for whom mpMRI
revealed a suspicion of more advanced disease, confirma-
tory biopsies showed a GG upgrade  2 in four (patients
3, 4, 6, and 7).
However, the false-negative rate was 4% (4/101).
The false-negative rate was defined as a lesion detected
on mpMRI with GG  2 which was not detected on
bpMRI. The difference did not reach statistical signif-
icance (McNemar’s test, P¼ 0.133).
Discussion
At present, guidelines recommend performing mpMRI
in men with low-risk PCa enrolled in AS to confirm
their eligibility and reduce the risk of missed occult
significant cancer (1). Here we compared the diagnostic
performance of a more simple and rapid bpMRI pro-
tocol with confirmatory mpMRI scans in selecting men
eligible for AS and assessed whether bpMRI missed
Fig. 1. Comparison of patient PI-RADS scores obtained from bpMRI and mpMRI results PI-RADS, prostate imaging reporting and
data system; mpMRI, multiparametric magnetic resonance imaging; bp, biparametric (MRI).
Table 2. Baseline characteristics.
Characteristics P value
Total patients (n) 101
Median age (years) SD (range) 64 6.3 (49–74) 0.9
Median total PSA (ng/mL)
SD (range)
6.3 4 (1.6–18) 1
Median prostate volume
(ng/mL) SD (range)
49 29 (25–199) 0.96
Median PSA density
(ng/mL) SD (range)
0.13 0.09
(0.04–0.56)
1
Clinical stage (n)
T1c 65
T2a 11
T2b 4
Tx 21
PI-RADS on bpMRI (n)
1 13
2 17
3 23
4 28
5 20
Lesions on bpMRI (n)
0 13
1 60
2 24
3 4
First set of biopsies (n)
GG 1 74
GG 2 27
SD, standard deviation; PSA, prostate-specific antigen; PI-RADS, prostate
imaging reporting and data system; bpMRI, biparametric magnetic reso-
nance imaging; GG, Gleason grade group.
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significant PCa lesions that were subsequently detected
by mpMRI. The variables are normality distributed but
with large enough sample sizes the violation of the nor-
mality assumption should not cause major problems
(18). Overall, we found no significant difference
between bpMRI and confirmatory mpMRI performed
in men three months after enrolment in AS. This indi-
cates that a rapid and simple pre-biopsy bpMRI per-
formed in the initial setting of detecting PCa also
suffices as an initial scan for AS eligibility and an addi-
tional confirmatory staging mpMRI performed shortly
after AS enrolment is not necessary. Prior studies have
evaluated and compared the diagnostic performance of
bpMRI and mpMRI in detecting PCa (18,19).
However, our study further assesses the ability of
bpMRI for the specific task of selecting men for AS,
which constitutes a selected patient cohort, as these
men have known low-risk PCa and their eligibility for
AS based on PSA, DRE, and biopsy findings is decided
after all the diagnostic results are available. While lim-
ited data are available for bpMRI to select men for AS,
our findings are consistent with a previous retrospective
study that compared the diagnostic accuracy of bpMRI
and mpMRI in detecting significant PCas in 204
patients (19). Six patients had suspicion of more
advanced disease, of which five were due to new
appearing lesions on mpMRI. Four of these men had
significant PCa detected on confirmatory biopsies. The
numbers are limited and larger prospective studies are
needed to confirm our conclusion. However, despite
the limited patient number, our study provides addi-
tional evidence for the reliability of using bpMRI in the
initial assessment of selecting men for AS. Overall, two
independent readers missed only four (4/204) and three
(3/204) significant cancers using bpMRI and zero
(0/204) and five (5/204) significant cancers using
mpMRI, respectively. Similarly, Kuhl et al. found no
significant differences in the diagnostic accuracy of
bpMRI and mpMRI in 542 men with elevated PSA
who underwent repeated prostate biopsies (20).
However, while bpMRI seems sufficient as an initial
eligibility-scan for AS, mpMRI still plays a role
during follow-up in monitoring the disease. Men
enrolled in AS undergo close surveillance, including
repeat biopsies after one year. Ideally, these biopsies
should be preceded by confirmatory mpMRI to identi-
fy possible disease progression and the limited number
of bpMRI missed significant lesions, if bpMRI was
used as an initial scan to confirm eligibility for AS.
Overall, mpMRI performed three months after
bpMRI raised suspicion of more advanced disease in
6% of our study patients, in which confirmatory biop-
sies revealed a GG upgrade in 4% (4/101 patients),
However, no patient had GG4 or GG5 PCa, and in
comparison to the contemporary well-established AS
cohorts and surveillance programs that do not include
MRI findings and where PCas are missed by TRUS-bx
in up to one-third of patients, the 4% false-negative
rate using bpMRI seems justifiable (21–23).
Moreover, as the time interval from bpMRI to
mpMRI was only three months, it might be that the
new lesions detected by mpMRI are not newly devel-
oped lesions, but rather lesions initially missed by the
reader or the bpMRI. In the case of patient 2 (with a
GG 1 on first and second biopsy set), biopsy cores from
the standard biopsies of the first set of biopsies detected
Table 3. Patients who had biopsies after mpMRI.
Patient bpMRI GG mpMRI
Comparable
MRIs (Y/N)
GG after
second biopsy
Comparable biopsy
results (Y/N)
1 PI-RADS 5 1 Same lesion Y 1 Y
2 PI-RADS 3 1 New lesion PI-RADS 3 N 1 Y
3 PI-RADS 3 1 New lesion PI-RADS 3 N 2 N
4 PI-RADS 5 1 Same lesion Y 3 N
5 PI-RADS 2 1 New lesion PI-RADS 4 N 2 N
6 No lesion 1 No lesion N 2 N
7 PI-RADS 4 2 Lesion growth N 3 N
8 PI-RADS 5 1 Same lesion Y 2 N
9 PI-RADS 3 2 New lesion PI-RADS 4 N 2 Y
mpMRI, multiparametric magnetic resonance imaging; bp, biparametric (MRI); GG, Gleason grade group; PI-RADS, prostate imaging reporting and
data system.
Table 4. Reader assessment changes in PI-RADS score.
MpMRI
PI-RADS 1-2 PI-RADS 3 PI-RADS 4-5 SUM
BpMRI
PI-RADS 1-2 29 0 1 30
PI-RADS 3 0 21 2 23
PI-RADS 4-5 0 0 48 48
SUM 29 21 51 101
PI, prostate imaging reporting and data system; SUM, summarized.
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what was seen as a new lesion found on mpMRI. But
as it is a GG 1, it cannot be expected that bpMRI or
mpMRI will detect it. In the case of patient 9 (with GG
2 on first and second biopsy set), standard biopsies also
detected the lesion which appeared as a new lesion on
mpMRI. The remaining patients with new lesions
(patients 3 and 5) were not detected by standard biop-
sies. But as standard biopsies are only biopsies and
thereby do not cover the whole gland, it cannot be
concluded that if the standard biopsy misses a lesion
then it is not there. This means that even though the
first set of standard biopsies misses the lesion, it might
still be there. This is also supported by the very short
time interval which makes the possibility of a new
lesion very unlikely. Furthermore, it is important to
realize that there will always be a risk of targeting
error when performing image-guided biopsies despite
careful efforts to align the MRI and TRUS images.
Biopsy targeting error was suspected in three patients
(all anterior lesions), of which two had a GG upgrade
following re-biopsy. This may be explained by the
fact that only 1–2 targeted biopsy cores was obtained
from each suspicious lesion in the initial biopsy
setting. Sampling errors may be reduced by spacing
biopsies and obtain more targeted cores per lesion
(focal saturation).
Our study has limitations. First, the study is a ret-
rospective analysis of prospectively collected data with
a limited number of patients who fulfilled the final
inclusion criteria. Because not all patients in our AS
cohort underwent a confirmatory mpMRI three
months after the initial diagnostic bpMRI, there
might be a selection bias for those who did.
Furthermore, because the bpMRI and mpMRI scans
were not performed at the same time point, we cannot
theoretically rule out disease progression. However, we
think it is reasonable to conclude that the additional
aggressive cancerous lesions (GG  2) detected by
mpMRI were not caused by disease progression, but
were missed in the initial assessment of bpMRI,
because low- and intermediate-risk PCas generally
develop slowly (17). Second, this study was performed
at a single center with one dedicated MRI physician
reading all the MRI scans and two highly experienced
TRUS operators performing all the biopsies. As a
result, no inter-reader analysis could be done. Less
experienced readers and operators might not achieve
the same diagnostic yield. However, we found a high
intra-reader agreement (Cohen’s Kappa¼ 0.94), which
corresponds with our previously reported inter-reader
agreement (Cohen’s Kappa¼ 0.84–0.87) comparing
bpMRI with mpMRI (19). Third, because we used
Fig. 2. BpMRI of patient 3. BpMRI of an anterior PI-RADS 3 lesion where targeted biopsies revealed a GG 1. PI-RADS, prostate
imaging reporting and data system; bpMRI, biparametric magnetic resonance imaging.
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biopsy results as standard reference, PCa lesions may
have been missed by both bpMRI, mpMRI, and biop-
sies. Furthermore, as only nine patients were re-
biopsied, we cannot exclude the possibility that MRI
invisible lesions would have been detected by standard
re-biopsies if all men regardless of mpMRI findings
underwent repeat biopsies (standard and targeted)
after three months. Thus, we acknowledge the limita-
tion of this being a retrospective study without prosta-
tectomy specimens as ideal comparing reference to
confirm presence or absence of missed PCa lesions.
And that the diagnostic and staging accuracy cannot
be evaluated precisely without because of this.
Furthermore, our numbers are limited and larger pro-
spective studies are needed to confirm our conclusion.
However, although the PROMIS study was performed
in biopsy-naı¨ve men and not in an AS cohort, the
study showed a good association between mpMRI sus-
picion and significant PCas, using 5-mm template sam-
pling as standard reference (4) with only limited added
value of TRUS-bx in mpMRI-negative men.
Furthermore, because all patients underwent standard
biopsies following initial bpMRI, including those with
low-suspicion bpMRI scans, using biopsies as standard
reference allowed us to compare outcomes that reflect
clinical practice. Fourth, because the bpMRI scans
were scored using a modified PI-RADS score,
equivocal scores of PI-RADS 3 in the peripheral zone
were not upgraded to PI-RADS 4 due to a lack
of positive dynamic contrast-enhanced findings.
However, this would only affect biopsy results strati-
fied by PI-RADS scores and not the overall outcomes,
because all PI-RADS 3 lesions were biopsied. Finally,
bpMRI was performed in biopsy-naı¨ve men and
mpMRI was performed in recently biopsied men.
Thus, the pre-test cancer prevalence differed (biopsy-
naı¨ve versus AS cohort), which might have influenced
the diagnostic performance of bpMRI and mpMRI.
Furthermore, post biopsy-related artefacts and
morphological changes in the prostate may have influ-
enced the sensitivity of mpMRI. However, it is a
generally recommended to wait 6–8 weeks after
biopsy before prostate MRI is performed to avoid arte-
fact from biopsy-related hemorrhage. Still, this does
not account for biopsy induced inflammation
or atrophy.
Fig. 3. MpMRI of patient 3. A new anterior PI-RADS 3 lesion as seen on the bpMRI. Repeat targeted biopsies revealed a Gleason
score upgrade to GG 2. PI-RADS, prostate imaging reporting and data system; mpMRI, multiparametric magnetic resonance imaging.
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Fig. 4. BpMRI of patient 4. BpMRI of an anterior PI-RADS 5 lesion where targeted biopsies revealed a GG 1. This raised suspicion of
targeting error. PI-RADS, prostate imaging reporting and data system; bpMRI, biparametric magnetic resonance imaging.
Fig. 5. MpMRI of patient 4. The same anterior PI-RADS 5 lesion as seen on the bpMRI. Repeat targeted biopsies revealed a Gleason
score upgrade to GG 3. PI-RADS, prostate imaging reporting and data system; mpMRI, multiparametric magnetic resonance imaging.
Thestrup et al. 9
Fig. 6. BpMRI of patient 9. BpMRI of an anterior PI-RADS 3 lesion where targeted biopsies revealed a GG 2. PI-RADS, prostate
imaging reporting and data system; bpMRI, biparametric magnetic resonance imaging.
Fig. 7. MpMRI of patient 9. The same anterior lesion as seen on the bpMRI but on mpMRI is upgraded to an PI-RADS 4. Repeat
targeted biopsies revealed a GG 2 again. PI-RADS, prostate imaging reporting and data system; mpMRI, multiparametric magnetic
resonance imaging.
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Despite these limitations, our data provide addition-
al evidence for the reliability of using bpMRI in the
initial assessment of selecting men for AS.
In conclusion, a rapid and simple bpMRI could be
used to select men eligible for AS and a confirmatory
mpMRI performed shortly after inclusion seems
unnecessary.
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